Archives

  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br CONCLUSIONS br Giving post SRS

    2022-05-25


    CONCLUSIONS
    Giving post-SRS systemic therapy to patients with Etoposide metas-tases and controlled extracranial disease may be an effective prophylaxis to reduce the risk of future brain relapse. The benefits of this approach on patients’ quality of life must be weighed against the costs of drug toxicity and the financial burden of treatment. Future studies should compare different treatment types to see if particular drug classes are more effective at reducing relapse risk and death. Additional randomized prospective trials are needed to further delineate the role of systemic therapy after SRS.
    REFERENCES
    1. Choong ES, Lo S, Drummond M, et al. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer. 2017;75:169-178.
    2. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS. Radiosurgery for mela-noma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012; 117:227-233.
    3. Nieder C, Marienhagen K, Dalhaug A, Aandahl G, Haukland E, Pawinski A. Impact of systemic treatment on survival after whole brain radio-therapy in patients with brain metastases. Med Oncol. 2014;31:927.
    4. Niwinska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of 
    5. Bourke RS, West CR, Chheda G, Tower DB. Ki-netics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intrave-nous injection in a primate. Cancer Res. 1973;33: 1735-1746.
    6. Miyajima M, Kusuhara H, Takahashi K, et al. Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system. J Pharm Sci. 2013;102:3309-3319.
    8. Morikawa A, Peereboom DM, Smith QR, et al. Clinical evidence for drug penetration of
    capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol. 2013;15(suppl):514.
    9. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res. 2005;11:1669-1674.
    11. Yule SM, Price L, Pearson ADJ, Boddy AV. Cyclo-phosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res. 1997;3:1985-1992.
    WORLD NEUROSURGERY -: e1-e10, - 2019 www.journals.elsevier.com/world-neurosurgery e9
    ORIGINAL ARTICLE
    TIMOUR AL-KHINDI ET AL. EFFECT OF POST-SRS SYSTEMIC THERAPY ON PATIENT OUTCOMES
    14. von Holst H, Knochenhauer E, Etoposide Blomgren H, et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien). 1990;104:13-16.
    15. Chang AY, Ying XX. Brain metastases from breast cancer and response to treatment with eribulin: a case series. Breast Cancer (Auckl). 2015;9:19-24.
    16. Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2:116-120.
    18. Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol. 2006;17:200-204.
    21. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009; 11:80-91.
    22. Chalmers AJ, Jackson A, Swaisland H, et al. Re-sults of stage 1 of the oparatic trial: a phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma. J Clin Oncol. 2014;32. abstract 2025.